ClinicalTrials.gg

Program

ARQ-154

A development code. Also written as “ARQ-154 Foam 0.3%”, “Roflumilast Foam” and “Roflumilast Foam 0.3%”.

Its studies are mostly in Dermatitis, Seborrheic · Psoriasis, led by Arcutis Biotherapeutics.

Furthest: phase 3, since Jul 13, 20215 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Arcutis Biotherapeutics50 open or runningphase 3since Jul 13, 2021Sep 13, 2019none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 13, 2019First study: phase 2 study in Dermatitis, SeborrheicFirst studyNCT04091646 · 226 enrolled · United States, Canada
  2. Oct 14, 2019Phase 2 study in Plaque PsoriasisNCT04128007 · 304 enrolled · United States, Australia, Bulgaria and more
  3. Jun 22, 2020Phase 2 study in Dermatitis, SeborrheicNCT04445987 · 408 enrolled · United States
  4. Jul 13, 2021Phase 3 study in Dermatitis, SeborrheicNCT04973228 · 457 enrolled · United States, Canada
  5. Dec 19, 2025Phase 1 study in PsoriasisNCT07340216 · 22 enrolled · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07340216Psoriasis · United States1CompletedApr 30, 202622
NCT04973228Dermatitis, Seborrheic · United States, Canada3CompletedApr 6, 2022457
NCT04445987Dermatitis, Seborrheic · United States2CompletedNov 19, 2022408
NCT04128007Plaque Psoriasis · United States, Australia, Bulgaria and more2CompletedSep 23, 2020304
NCT04091646Dermatitis, Seborrheic · United States, Canada2CompletedAug 18, 2020226

How it is read

Names in the registry

  • “ARQ-154 Foam 0.3%”, 1 entry
  • “ARQ-154”, 1 entry
  • “Roflumilast Foam”, 1 entry
  • “Roflumilast Foam 0.3%”, 1 entry
  • “Roflumilast foam 0.3%”, 1 entry

Codes read as this program: ARQ154.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.